Clinical trial
Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With…
NCT00467987 · University at Buffalo, Other · Terminated
Key facts
| NCT number | NCT00467987 |
|---|---|
| Title | Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism |
| Official title | Effect of Androgel on Atherogenesis, Inflammation, Cardiovascular Risk Factors And Adiposity in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism.: a Prospective, Randomized and Controlled-Study |
| Lead sponsor | University at Buffalo, Other |
| Collaborators | Solvay Pharmaceuticals Industry |
| Status | Terminated |
| Study type | Interventional |
| Conditions | Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism |
| Intervention type | Drug |
| Interventions | androgel, placebo |
| Enrollment | 47 |
| Start date | Jun 1, 2007 |
| Primary completion | Mar 1, 2018 |
| Completion | Oct 11, 2018 |
| First posted | May 1, 2007 |
| Last update posted | Feb 6, 2024 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: